SCA
AMED

Stonebridge Capital Advisors’s Amedisys AMED Stock Holding History

Stonebridge Capital Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5
Closed – – 972
2022
Q3 		$0 Buy
+5
New +$596 ﹤0.01% 995
2021
Q3 		– Sell
-8
Closed -$2K – 952
2021
Q2 		$2K Buy
8
+4
+100% +$1.05K ﹤0.01% 912
2021
Q1 		$1K Buy
+4
New +$1.13K ﹤0.01% 880

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Stonebridge Capital Advisors's AMED Position: Q4 2022 in Review

Stonebridge Capital Advisors sold out of Amedisys (AMED) in Q4 2022, closing a stake of 5 shares.

Stonebridge Capital Advisors first reported a position in AMED in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q2 2021. 277 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

  • Stonebridge Capital Advisors reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 5 Amedisys shares in Q4 2022.
  • Stonebridge Capital Advisors first reported a position in Amedisys in Q1 2021 and held it in 3 quarters.
  • Stonebridge Capital Advisors's Amedisys position peaked at $2K in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.